BRISTOL-MYERS SQUIBB COMPANY Interest Expense
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Interest Expense of $425.00 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-04-25.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-04-25
- BRISTOL-MYERS SQUIBB COMPANY interest expense for the quarter ending 2024-03-31 was $425.00M, a 47.57% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY interest expense for the quarter ending 2023-12-31 was $316.00M, a 7.48% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY interest expense for the quarter ending 2023-09-30 was $280.00M, a 6.35% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY interest expense for the quarter ending 2023-06-30 was $282.00M, a 9.90% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY interest expense for fiscal 2023 was $1.17B, a 5.36% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY interest expense for fiscal 2022 was $1.23B, a 7.65% decline from fiscal 2021.
- BRISTOL-MYERS SQUIBB COMPANY interest expense for fiscal 2021 was $1.33B, a 6.06% decline from fiscal 2020.
- BRISTOL-MYERS SQUIBB COMPANY interest expense for fiscal 2020 was $1.42B, a 116.46% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $425.00M 10-Q · filed 2024-04-25 | $741.00M derived: sum of 2 quarters · filed 2024-04-25 | $1.02B derived: sum of 3 quarters · filed 2024-04-25 | $1.30B derived: sum of 4 quarters · filed 2024-04-25 |
| 2023-12-31 | $316.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $596.00M derived: sum of 2 quarters · filed 2024-02-13 | $878.00M derived: sum of 3 quarters · filed 2024-02-13 | $1.17B 10-K · filed 2024-02-13 |
| 2023-09-30 | $280.00M 10-Q · filed 2023-10-26 | $562.00M derived: sum of 2 quarters · filed 2023-10-26 | $850.00M 10-Q · filed 2023-10-26 | $1.14B derived: sum of 4 quarters · filed 2024-04-25 |
| 2023-06-30 | $282.00M 10-Q · filed 2023-07-27 | $570.00M 10-Q · filed 2023-07-27 | $864.00M derived: sum of 3 quarters · filed 2024-04-25 | $1.16B derived: sum of 4 quarters · filed 2024-04-25 |
| 2023-03-31 | $288.00M 10-Q · filed 2024-04-25 | $582.00M derived: sum of 2 quarters · filed 2024-04-25 | $881.00M derived: sum of 3 quarters · filed 2024-04-25 | $1.19B derived: sum of 4 quarters · filed 2024-04-25 |
| 2022-12-31 | $294.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $593.00M derived: sum of 2 quarters · filed 2024-02-13 | $906.00M derived: sum of 3 quarters · filed 2024-02-13 | $1.23B 10-K · filed 2024-02-13 |
| 2022-09-30 | $299.00M 10-Q · filed 2023-10-26 | $612.00M derived: sum of 2 quarters · filed 2023-10-26 | $938.00M 10-Q · filed 2023-10-26 | $1.26B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $313.00M 10-Q · filed 2023-07-27 | $639.00M 10-Q · filed 2023-07-27 | $962.00M derived: sum of 3 quarters · filed 2024-02-13 | $1.29B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $326.00M 10-Q · filed 2023-04-27 | $649.00M derived: sum of 2 quarters · filed 2024-02-13 | $977.00M derived: sum of 3 quarters · filed 2024-02-13 | $1.31B derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $323.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $651.00M derived: sum of 2 quarters · filed 2024-02-13 | $981.00M derived: sum of 3 quarters · filed 2024-02-13 | $1.33B 10-K · filed 2024-02-13 |
| 2021-09-30 | $328.00M 10-Q · filed 2022-10-26 | $658.00M derived: sum of 2 quarters · filed 2022-10-26 | $1.01B 10-Q · filed 2022-10-26 | $1.37B derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $330.00M 10-Q · filed 2022-07-27 | $683.00M 10-Q · filed 2022-07-27 | $1.04B derived: sum of 3 quarters · filed 2023-02-14 | $1.38B derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $353.00M 10-Q · filed 2022-04-29 | $708.00M derived: sum of 2 quarters · filed 2023-02-14 | $1.05B derived: sum of 3 quarters · filed 2023-02-14 | $1.41B derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $355.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $701.00M derived: sum of 2 quarters · filed 2023-02-14 | $1.06B derived: sum of 3 quarters · filed 2023-02-14 | $1.42B 10-K · filed 2023-02-14 |
| 2020-09-30 | $346.00M 10-Q · filed 2021-10-27 | $703.00M derived: sum of 2 quarters · filed 2021-10-27 | $1.06B 10-Q · filed 2021-10-27 | $1.34B derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | $357.00M 10-Q · filed 2021-07-28 | $719.00M 10-Q · filed 2021-07-28 | $998.00M derived: sum of 3 quarters · filed 2022-02-09 | $1.21B derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $362.00M 10-Q · filed 2021-04-29 | $641.00M derived: sum of 2 quarters · filed 2022-02-09 | $850.00M derived: sum of 3 quarters · filed 2022-02-09 | $973.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | $279.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $488.00M derived: sum of 2 quarters · filed 2022-02-09 | $611.00M derived: sum of 3 quarters · filed 2022-02-09 | $656.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $209.00M 10-Q · filed 2020-11-05 | $332.00M derived: sum of 2 quarters · filed 2020-11-05 | $377.00M 10-Q · filed 2020-11-05 | $425.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | $123.00M 10-Q · filed 2020-08-06 | $168.00M 10-Q · filed 2020-08-06 | $216.00M derived: sum of 3 quarters · filed 2021-02-10 | $260.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $45.00M 10-Q · filed 2020-05-07 | $93.00M derived: sum of 2 quarters · filed 2021-02-10 | $137.00M derived: sum of 3 quarters · filed 2021-02-10 | $182.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $48.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $92.00M derived: sum of 2 quarters · filed 2021-02-10 | $137.00M derived: sum of 3 quarters · filed 2021-02-10 | $183.00M 10-K · filed 2021-02-10 |
| 2018-09-30 | $44.00M 10-Q · filed 2019-10-31 | $89.00M derived: sum of 2 quarters · filed 2019-10-31 | $135.00M 10-Q · filed 2019-10-31 | $186.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $45.00M 10-Q · filed 2019-07-25 | $91.00M 10-Q · filed 2019-07-25 | $142.00M derived: sum of 3 quarters · filed 2020-02-24 | $190.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $46.00M 10-Q · filed 2019-04-25 | $97.00M derived: sum of 2 quarters · filed 2020-02-24 | $145.00M derived: sum of 3 quarters · filed 2020-02-24 | $197.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $51.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $99.00M derived: sum of 2 quarters · filed 2020-02-24 | $151.00M derived: sum of 3 quarters · filed 2020-02-24 | $196.00M 10-K · filed 2020-02-24 |
| 2017-09-30 | $48.00M 10-Q · filed 2018-10-25 | $100.00M derived: sum of 2 quarters · filed 2018-10-25 | $145.00M 10-Q · filed 2018-10-25 | $185.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $52.00M 10-Q · filed 2018-07-26 | $97.00M 10-Q · filed 2018-07-26 | $137.00M derived: sum of 3 quarters · filed 2019-02-25 | $179.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | $45.00M 10-Q · filed 2018-04-26 | $85.00M derived: sum of 2 quarters · filed 2019-02-25 | $127.00M derived: sum of 3 quarters · filed 2019-02-25 | $169.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $82.00M derived: sum of 2 quarters · filed 2019-02-25 | $124.00M derived: sum of 3 quarters · filed 2019-02-25 | $167.00M 10-K · filed 2019-02-25 |
| 2016-09-30 | $42.00M 10-Q · filed 2017-10-26 | $84.00M derived: sum of 2 quarters · filed 2017-10-26 | $127.00M 10-Q · filed 2017-10-26 | $170.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $42.00M 10-Q · filed 2017-07-27 | $85.00M 10-Q · filed 2017-07-27 | $128.00M derived: sum of 3 quarters · filed 2018-02-13 | $169.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $43.00M 10-Q · filed 2017-04-27 | $86.00M derived: sum of 2 quarters · filed 2018-02-13 | $127.00M derived: sum of 3 quarters · filed 2018-02-13 | $176.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $43.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $84.00M derived: sum of 2 quarters · filed 2018-02-13 | $133.00M derived: sum of 3 quarters · filed 2018-02-13 | $184.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | $41.00M 10-Q · filed 2016-10-27 | $90.00M derived: sum of 2 quarters · filed 2016-10-27 | $141.00M 10-Q · filed 2016-10-27 | $194.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $49.00M 10-Q · filed 2016-07-28 | $100.00M 10-Q · filed 2016-07-28 | $153.00M derived: sum of 3 quarters · filed 2017-02-21 | $203.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $51.00M 10-Q · filed 2016-04-28 | $104.00M derived: sum of 2 quarters · filed 2017-02-21 | $154.00M derived: sum of 3 quarters · filed 2017-02-21 | $200.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $53.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $103.00M derived: sum of 2 quarters · filed 2017-02-21 | $149.00M derived: sum of 3 quarters · filed 2017-02-21 | $203.00M 10-K · filed 2017-02-21 |
| 2014-09-30 | $50.00M 10-Q · filed 2015-10-27 | $96.00M derived: sum of 2 quarters · filed 2015-10-27 | $150.00M 10-Q · filed 2015-10-27 | $203.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $46.00M 10-Q · filed 2015-07-23 | $100.00M 10-Q · filed 2015-07-23 | $153.00M derived: sum of 3 quarters · filed 2016-02-12 | $199.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $54.00M 10-Q · filed 2015-04-28 | $107.00M derived: sum of 2 quarters · filed 2016-02-12 | $153.00M derived: sum of 3 quarters · filed 2016-02-12 | $203.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $53.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $99.00M derived: sum of 2 quarters · filed 2016-02-12 | $149.00M derived: sum of 3 quarters · filed 2016-02-12 | $199.00M 10-K · filed 2016-02-12 |
| 2013-09-30 | $46.00M 10-Q · filed 2014-10-24 | $96.00M derived: sum of 2 quarters · filed 2014-10-24 | $146.00M 10-Q · filed 2014-10-24 | $197.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $50.00M 10-Q · filed 2014-07-24 | $100.00M 10-Q · filed 2014-07-24 | $151.00M derived: sum of 3 quarters · filed 2015-02-13 | $199.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $50.00M 10-Q · filed 2014-04-29 | $101.00M derived: sum of 2 quarters · filed 2015-02-13 | $149.00M derived: sum of 3 quarters · filed 2015-02-13 | $190.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $51.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $99.00M derived: sum of 2 quarters · filed 2015-02-13 | $140.00M derived: sum of 3 quarters · filed 2015-02-13 | $182.00M 10-K · filed 2015-02-13 |
| 2012-09-30 | $48.00M 10-Q · filed 2013-10-23 | $89.00M derived: sum of 2 quarters · filed 2013-10-23 | $131.00M 10-Q · filed 2013-10-23 | $173.00M derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-06-30 | $41.00M 10-Q · filed 2013-07-25 | $83.00M 10-Q · filed 2013-07-25 | $125.00M derived: sum of 3 quarters · filed 2014-02-14 | $165.00M derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-03-31 | $42.00M 10-Q · filed 2013-04-25 | $84.00M derived: sum of 2 quarters · filed 2014-02-14 | $124.00M derived: sum of 3 quarters · filed 2014-02-14 | $156.00M derived: sum of 4 quarters · filed 2014-02-14 |
| 2011-12-31 | $42.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $82.00M derived: sum of 2 quarters · filed 2014-02-14 | $114.00M derived: sum of 3 quarters · filed 2014-02-14 | $145.00M 10-K · filed 2014-02-14 |
| 2011-09-30 | $40.00M 10-Q · filed 2011-10-27 | $72.00M derived: sum of 2 quarters · filed 2011-10-27 | $103.00M 10-Q · filed 2011-10-27 | $145.00M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $32.00M 10-Q · filed 2011-07-28 | $63.00M 10-Q · filed 2011-07-28 | $105.00M derived: sum of 3 quarters · filed 2013-02-15 | $143.00M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-03-31 | $31.00M 10-Q · filed 2011-04-28 | $73.00M derived: sum of 2 quarters · filed 2013-02-15 | $111.00M derived: sum of 3 quarters · filed 2013-02-15 | $143.00M derived: sum of 4 quarters · filed 2013-02-15 |
| 2010-12-31 | $42.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $80.00M derived: sum of 2 quarters · filed 2013-02-15 | $112.00M derived: sum of 3 quarters · filed 2013-02-15 | $145.00M 10-K · filed 2013-02-15 |
| 2010-09-30 | $38.00M 10-Q · filed 2011-10-27 | $70.00M derived: sum of 2 quarters · filed 2011-10-27 | $103.00M 10-Q · filed 2011-10-27 | $146.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | $32.00M 10-Q · filed 2011-07-28 | $65.00M 10-Q · filed 2011-07-28 | $108.00M derived: sum of 3 quarters · filed 2012-02-17 | $155.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | $33.00M 10-Q · filed 2011-04-28 | $76.00M derived: sum of 2 quarters · filed 2012-02-17 | $123.00M derived: sum of 3 quarters · filed 2012-02-17 | $165.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2009-12-31 | $43.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $90.00M derived: sum of 2 quarters · filed 2012-02-17 | $132.00M derived: sum of 3 quarters · filed 2012-02-17 | $184.00M 10-K · filed 2012-02-17 |
| 2009-09-30 | $47.00M 10-Q · filed 2010-10-26 | $89.00M derived: sum of 2 quarters · filed 2010-10-26 | $141.00M 10-Q · filed 2010-10-26 | |
| 2009-06-30 | $42.00M 10-Q · filed 2010-07-22 | $94.00M 10-Q · filed 2010-07-22 | ||
| 2008-12-31 | $310.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |